Keytruda and Rectal haemorrhage - a phase IV clinical study of FDA data

Summary:

Rectal haemorrhage is reported as a side effect among people who take Keytruda (pembrolizumab), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Lenvima, and have Endometrial cancer.

The phase IV clinical study analyzes which people have Rectal haemorrhage when taking Keytruda. It is created by eHealthMe based on reports of 57,304 people who have side effects when taking Keytruda from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Rectal haemorrhage?

Rectal haemorrhage (bleeding from anus) is found to be associated with 1,729 drugs and 1,597 conditions by eHealthMe. Check the latest studies of Rectal haemorrhage.

On Jul, 16, 2026

57,304 people reported to have side effects when taking Keytruda.
Among them, 57 people (0.1%) have Rectal haemorrhage.

Could Keytruda cause Rectal haemorrhage?

Among these 57 people:

How long have people been on Keytruda when they have Rectal haemorrhage? *

What is the gender of people who have Rectal haemorrhage when taking Keytruda? *

female: 77.19 %
male: 22.81 %

What is the age of people who have Rectal haemorrhage when taking Keytruda? *

What are other drugs people take besides Keytruda? *

What are other side effects people have besides Rectal haemorrhage? *

Diarrhea: 14 people, 24.56%
Nosebleed (bleeding from nose): 8 people, 14.04%
Colitis (inflammation of colon): 8 people, 14.04%
Weakness: 7 people, 12.28%
Rashes (redness): 7 people, 12.28%
Stomatitis (inflammation of mucous membrane of mouth): 6 people, 10.53%
Anaemia (lack of blood): 5 people, 8.77%
High Blood Pressure: 5 people, 8.77%
Constipation: 5 people, 8.77%
Fatigue (feeling of tiredness): 5 people, 8.77%

What are the existing conditions these people have? *

Endometrial Cancer: 20 people, 35.09%
Non-Small Cell Lung Cancer Stage Iv: 4 people, 7.02%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 4 people, 7.02%
Endometrial Neoplasm (tumour of uterus wall): 4 people, 7.02%
Pneumonia: 3 people, 5.26%
Fever: 3 people, 5.26%
High Blood Pressure: 2 people, 3.51%
Lung Cancer - Non-Small Cell (lung cancer): 2 people, 3.51%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 1.75%
Hodgkin's Lymphoma (cancer originating from white blood cells): 1 person, 1.75%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and have Rectal haemorrhage?

- Check whether Rectal haemorrhage is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keytruda:

Keytruda (57,404 reports)

Browse all side effects of Keytruda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rectal haemorrhage:

Rectal haemorrhage (1,729 drugs)

Browse all the conditions that are associated with Rectal haemorrhage:

Rectal haemorrhage (1,597 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pembrolizumab (the active ingredients of Keytruda) and Keytruda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.